B+
Bull case
25%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-07-01 · RankAlpha Sentiment Codex
CTSO
CytoSorbentsFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The best bull argument is that CTSO still has live regulatory optionality around DrugSorb-related FDA discussions while Q1 showed direct-sales growth outside Germany, lower operating loss, and early benefits from prior cost cuts [#SEC-8K-2026-05-13] [#8-K-2026-06-25].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Going-concern risk remains explicit in the 10-Q, with management noting additional capital may be required if needed funding is not available [#10-Q-2026-05-13].
Momentum
79
Value
37
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.30 · Bull $0.70 · Bear $0.15Analysis 2026-07-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $47.50
Why
Momentum79 · Δ7d -
Value37 · Δ7d -0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Going-concern risk remains explicit in the 10-Q, with management noting additional capital may be required if needed funding is not available [#10-Q-2026-05-13].
- • Gross margin fell to 69% from 71% because of deliberately reduced production volumes to lower inventory, so margin recovery still needs proof [#SEC-8K-2026-05-13].
- • The bear case is that modest top-line growth, sub-$1 share price, going-concern language, and dependence on future financing or regulatory progress leave the equity highly vulnerable if August FDA discussions do not translate into a clearer approval path or if commercial recovery stays uneven [#10-Q-2026-05-13] [#8-K-2026-06-25].
Catalyst clock
2026-08-31
August 2026 FDA pre-submission meetings on ticagrelor and DOAC programs
Lead driver: Value · See fundamentals
Momentum
79
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 78.8 / Value 36.6 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-01. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.30
Analysis reference price unavailable
Analysis 2026-07-01 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.15
Analysis reference price unavailable
Analysis 2026-07-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$23.7M
Beta
1.39
Shares Out
62.84M
P/E (TTM) · Derived
-0.1
P/S (TTM)
1.22
P/FCF (TTM) · Derived
-2.55
Rev YoY
+0.2%
EPS YoY
-342.4%
Gross Margin
+71.6%
Op Margin
-31.6%
Net Debt
$23.13M
Current Ratio
0.66
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data